New developments for antibody-drug conjugate-based therapeutic approaches
about
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugateTime-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.A novel excision selection method for isolation of antibodies binding antigens expressed specifically by rare cells in tissue sectionsFrom Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).Stable and Potent Selenomab-Drug Conjugates.Utilization of Selenocysteine for Site-Specific Antibody Conjugation.Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Antibody drug conjugates.TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Novel Molecular Multilevel Targeted Antitumor AgentsDevelopment and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.Relationship between Surface Properties and In Vitro Drug Release from Compressed Matrix Containing Polymeric Materials with Different Hydrophobicity Degrees.Development of a facile antibody-drug conjugate platform for increased stability and homogeneityRecent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.Mass spectrometric characterization of protein structures and protein complexes in condensed and gas phase.Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.Targeting the N terminus for site-selective protein modification.αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.Analytical techniques for the characterization of Antibody Drug Conjugates: Challenges and prospects.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays.Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.
P2860
Q30101057-103E40F4-EBD6-4B54-A1D6-C7C0374E61E4Q33739302-110149A4-3F1E-4453-83EA-BFFBD3DA21BCQ33845533-2E155AB3-0337-4235-9B96-52C2EF015150Q36332226-04DB0C2A-6142-4709-B516-DD286C2913C7Q37561359-2E1FC4D0-2737-4C95-8162-8C498ADF88CFQ38432502-14CCF373-ACA8-423E-BCF7-8BC3A5CD2DDFQ38432937-55B9CE8E-EF25-4976-BE99-C4E53E6F3FCFQ38703584-F1F5A6DD-8260-4369-82FF-F8F5A74C1E9FQ38726286-5F48FA8B-C0A6-4939-85E6-410815C282D2Q38736346-309A782C-BE88-4F1E-AC1A-1A103B2012F5Q38738155-C909AB95-97C3-4525-855D-FA2A4FEF4A01Q38873862-22CB8982-AD6F-49D3-B838-E88B09A54AC3Q38920996-B13973A1-37AB-406F-AF79-1ED55DA7BA29Q38922319-EC3EEFCD-2376-46B3-91A8-4E6953933D65Q39030222-C76C417C-7D42-4C07-93AD-21FDEAE5816FQ39210427-21FC04D1-8CAF-4300-9666-532C0CFA84C6Q39394159-3D01F1CA-D899-4825-831B-7A11E7A1A5CBQ41221244-2BA874B0-D7A0-49DD-A966-B7537D196A6EQ41280225-941E9B10-2C9E-4B73-9EC3-04A3A6BE45ECQ41429679-3E01A01A-54E4-4546-969F-C1AC48DBF56AQ41661216-A07B61AF-4374-4685-83F8-A94B7FFBE235Q41709078-5BB08EBA-FABF-4DAD-9E16-3E7B16B0BA52Q42135259-DC19877E-3263-489A-8A57-185954149E4EQ42293596-B504B7DD-FA2B-45BF-8C4D-E4FDCA92067EQ45728543-89E654B9-5E1C-4A49-B776-A2946CBDE528Q45875443-A6697075-4118-401B-903C-C82480160B9BQ46219687-FE1F17C0-FE02-45DE-8A5C-AA538C529FDAQ46357738-ADE0F248-782B-412B-9E99-BBCC27A33A9EQ46463952-5EE07E7D-55C5-4381-B492-CB9D3695A55DQ47097144-B59C512F-B271-4228-B4E1-ECCFAA0A593CQ47221234-016C13FD-CF76-4FC0-A38B-B7FBB95C14D6Q47271330-C8270342-27D7-4048-BFE0-80813624C8F4Q47568807-71AA0AB9-918D-4FCD-98D4-47D3C64B6D6DQ48199774-9671AEFC-E947-4D6C-8213-F0B301344AA6Q48222378-FB7BD64F-D805-4A9B-8E1F-69994B4649C6Q48243258-CA118303-033D-406A-9228-8EF011A9D6DEQ49831027-29756FA5-395E-4B6B-9CC7-EFBA96166A2DQ50046714-7C1F6C1E-7012-49A5-9E04-4960625100E9Q50637272-9218D8AF-8AA5-4F68-BB78-96767B83C03CQ50922680-7C0D82B3-7075-4C5C-ACA5-7C1605F19039
P2860
New developments for antibody-drug conjugate-based therapeutic approaches
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
New developments for antibody-drug conjugate-based therapeutic approaches
@ast
New developments for antibody-drug conjugate-based therapeutic approaches
@en
New developments for antibody-drug conjugate-based therapeutic approaches
@nl
type
label
New developments for antibody-drug conjugate-based therapeutic approaches
@ast
New developments for antibody-drug conjugate-based therapeutic approaches
@en
New developments for antibody-drug conjugate-based therapeutic approaches
@nl
prefLabel
New developments for antibody-drug conjugate-based therapeutic approaches
@ast
New developments for antibody-drug conjugate-based therapeutic approaches
@en
New developments for antibody-drug conjugate-based therapeutic approaches
@nl
P1476
New developments for antibody-drug conjugate-based therapeutic approaches
@en
P2093
Bart Ecg de Goeij
John M Lambert
P356
10.1016/J.COI.2016.02.008
P407
P577
2016-06-01T00:00:00Z